Pay in 4 interest-free payments of $6.75 Learn more
Ships within 48 hours · Estimated delivery Aug 17 - Aug 22
Lancet Diabetes Endocrinol 2024;12:63142
Consistent with the base-case analysis, sensitivity analyses demonstrated that using GLP-1RAs versus insulin was either cost-saving or cost-effective, except for the analyses where the treatment effectiveness was estimated based on the AT scenario in the second and third sensitivity analyses, showing that a GLP-1RA versus insulin therapy was not cost-effective for averting one case of all-cause death from the payer perspective
Pros & Cons: What to Weigh Here are the upsides and risksso you (and your doctor) can decide carefully
Areas Served Lafayette Baton Rouge Alexandria Lake Charles References Mller TD, Finan B, Bloom SR, DAlessio D, Drucker DJ, Flatt PR, Fritsche A, Gribble F, Grill HJ, Habener JF, Holst JJ, Langhans W, Meier JJ, Nauck MA, Perez-Tilve D, Pocai A, Reimann F, Sandoval DA, Schwartz TW, Seeley RJ, Stemmer K, Tang-Christensen M, Woods SC, DiMarchi RD, Tschp MH
User performance evaluation of four blood glucose monitoring systems applying ISO 15197:2013 accuracy criteria and calculation of insulin dosing errors
Can GLP Face Be Prevented
US$ 22.50
US$ 23.07
US$ 24.00
US$ 22.17
US$ 21.08
